Papers - NIIOKA Takenori
-
Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation.
Kagaya Hideaki, Niioka Takenori, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo
Xenobiotica 47 ( 10 ) 916 - 922 2017.10
-
Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka Takenori, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Yamamoto Ryohei, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo
Clin Exp Nephrol 21 ( 5 ) 787 - 796 2017.10
-
Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
Okuda Yuji, Sato Kazuhiro, Sudo Kazuhisa, Hasegawa Yukiyasu, Asano Mariko, Miura Hajime, Takeda Masahide, Sano Masaaki, Watanabe Hiroyuki, Kobayashi Hiroyuki, Niioka Takenori, Miura Masatomo, Ito Hiroshi
Cancer Chemother Pharmacol 79 ( 5 ) 1013 - 1020 2017.5
-
Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.
Numakura Kazuyuki, Tsuchiya Norihiko, Kagaya Hideaki, Takahashi Makoto, Tsuruta Hiroshi, Inoue Takamitsu, Narita Shintaro, Huang Mingguo, Satoh Shigeru, Niioka Takenori, Miura Masatomo, Habuchi Tomonori
Anticancer Drugs 28 ( 1 ) 97 - 103 2017.1
-
Quantification of Interstitial Fibrosis in Renal Allografts and Clinical Correlates of Long-Term Graft Function.
Nara Mizuho, Komatsuda Atsushi, Numakura Kazuyuki, Saito Mitsuru, Inoue Takamitsu, Niioka Takenori, Miura Masatomo, Mitobe Yoko, Okuyama Shin, Takahashi Naoto, Habuchi Tomonori, Satoh Shigeru
Am J Nephrol 46 ( 3 ) 187 - 194 2017
-
Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.
Kobayashi Takahiro, Niioka Takenori, Miura Masatomo, Takahashi Naoto
Ann Hematol 95 ( 12 ) 2087 - 2088 2016.12
-
Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
Yamashita Takaya, Fujishima Naohito, Miura Masatomo, Niioka Takenori, Abumiya Maiko, Shinohara Yoshinori, Ubukawa Kumi, Nara Miho, Fujishima Masumi, Kameoka Yoshihiro, Tagawa Hiroyuki, Hirokawa Makoto, Takahashi Naoto
Cancer Chemother Pharmacol 78 ( 1 ) 111 - 118 2016.7
-
Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Takeda Masahide, Okuda Yuji, Asano Mariko, Ito Hiroshi, Miura Masatomo
Med Oncol 33 ( 6 ) 57 - 57 2016.6
-
Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients.
Niioka Takenori, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Yamamoto Ryohei, Akamine Yumiko, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo
Int J Urol 23 ( 6 ) 484 - 490 2016.6
-
Effect of CYP3A5 and ABCB1 polymorphisms on the interaction between tacrolimus and itraconazole in patients with connective tissue disease.
Togashi Masaru, Niioka Takenori, Komatsuda Atsushi, Nara Mizuho, Okuyama Shin, Omokawa Ayumi, Abumiya Maiko, Wakui Hideki, Takahashi Naoto, Miura Masatomo
Eur J Clin Pharmacol 71 ( 9 ) 1091 - 1097 2015.9
-
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masatomo
Clin Lung Cancer 16 ( 4 ) 274 - 281 2015.7
-
Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.
Niioka Takenori, Kagaya Hideaki, Saito Mitsuru, Inoue Takamitsu, Numakura Kazuyuki, Habuchi Tomonori, Satoh Shigeru, Miura Masatomo
Int J Mol Sci 16 ( 1 ) 1840 - 1854 2015.1
-
Effects of CYP3A5 polymorphism and the tacrolimus 12 h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis.
Niioka Takenori, Komatsuda Atsushi, Kato Shotaro, Togashi Masaru, Okuyama Shin, Omokawa Ayumi, Nara Mizuho, Wakui Hideki, Takahashi Naoto, Miura Masatomo
Xenobiotica 45 ( 12 ) 1147 - 1153 2015
-
Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation.
Numakura Kazuyuki, Kagaya Hideaki, Yamamoto Ryohei, Komine Naoki, Saito Mitsuru, Hiroshi Tsuruta, Akihama Susumu, Inoue Takamitsu, Narita Shintaro, Tsuchiya Norihiko, Habuchi Tomonori, Niioka Takenori, Miura Masatomo, Satoh Shigeru
Dis Markers 2015 179434 - 179434 2015
-
Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation.
Satoh Shigeru, Niioka Takenori, Kagaya Hideaki, Numakura Kazuyuki, Inoue Takamitsu, Saito Mitsuru, Komine Naoki, Narita Shintaro, Tsuchiya Norihiko, Habuchi Tomonori, Miura Masatomo
Pharmacogenomics 15 ( 11 ) 1495 - 1506 2014.8
-
A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients.
Shida Seiji, Takahashi Naoto, Miura Masatomo, Niioka Takenori, Matsumoto Morio, Hagihara Masao, Kobayashi Takahiro, Abumiya Maiko, Kameoka Yoshihiro, Fujishima Naohito, Tagawa Hiroyuki, Hirokawa Makoto, Sawada Kenichi
Ther Drug Monit 36 ( 4 ) 505 - 509 2014.8
-
Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.
Takahashi Naoto, Miura Masatomo, Kuroki Jun, Mitani Kinuko, Kitabayashi Atsushi, Sasaki Osamu, Kimura Hideo, Imai Kiyotoshi, Tsukamoto Norifumi, Noji Hideyoshi, Kondo Takeshi, Motegi Mutsuhito, Kato Yuichi, Mita Masayuki, Saito Hajime, Yoshida Chikashi, Torimoto Yoshihiro, Kimura Tomofumi, Wano Yuji, Nomura Jun, Yamamoto Satoshi, Mayama Ko, Honma Riko, Sugawara Tomohiro, Sato Shinji, Shinagawa Atsushi, Abumiya Maiko, Niioka Takenori, Harigae Hideo, Sawada Kenichi
Biomark Res 2 ( 1 ) 6 - 6 2014.3
-
A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.
Miura Masatomo, Sato Kazuhiro, Miura Hajime, Niioka Takenori, Kobayashi Hiroyuki, Narita Chihiro, Ito Hiroshi
Ther Drug Monit 36 ( 1 ) 24 - 29 2014.2
-
Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y, Motoyama S, Niioka T, Miura M
J Clin Pharm Ther 38 ( 6 ) 498 - 503 2013.12
-
Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.
Niioka Takenori, Kagaya Hideaki, Miura Masatomo, Numakura Kazuyuki, Saito Mitsuru, Inoue Takamitsu, Habuchi Tomonori, Satoh Shigeru
Eur J Clin Pharmacol 69 ( 9 ) 1659 - 1665 2013.9